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Background. The high-throughput genotyping chips have contributed greatly to genome-wide association (GWA) studies to
identify novel disease susceptibility single nucleotide polymorphisms (SNPs). The high-density chips are designed using two
different SNP selection approaches, the direct gene-centric approach, and the indirect quasi-random SNPs or linkage
disequilibrium (LD)-based tagSNPs approaches. Although all these approaches can provide high genome coverage and
ascertain variants in genes, it is not clear to which extent these approaches could capture the common genic variants. It is also
important to characterize and compare the differences between these approaches. Methodology/Principal Findings. In our
study, by using both the Phase II HapMap data and the disease variants extracted from OMIM, a gene-centric evaluation was
first performed to evaluate the ability of the approaches in capturing the disease variants in Caucasian population. Then the
distribution patterns of SNPs were also characterized in genic regions, evolutionarily conserved introns and nongenic regions,
ontologies and pathways. The results show that, no mater which SNP selection approach is used, the current high-density SNP
chips provide very high coverage in genic regions and can capture most of known common disease variants under HapMap
frame. The results also show that the differences between the direct and the indirect approaches are relatively small. Both have
similar SNP distribution patterns in these gene-centric characteristics. Conclusions/Significance. This study suggests that the
indirect approaches not only have the advantage of high coverage but also are useful for studies focusing on various
functional SNPs either in genes or in the conserved regions that the direct approach supports. The study and the annotation of
characteristics will be helpful for designing and analyzing GWA studies that aim to identify genetic risk factors involved in
common diseases, especially variants in genes and conserved regions.
Citation: Dong C, Qian Z, Jia P, Wang Y, Huang W, et al (2007) Gene-Centric Characteristics of Genome-Wide Association Studies. PLoS ONE 2(12):
e1262. doi:10.1371/journal.pone.0001262
INTRODUCTION
Genome-wide association (GWA) studies using high-throughput
single nucleotide polymorphism (SNP) chips have shown the
power to identify novel disease susceptibility loci [1–3]. Two SNP
selection approaches are proposed to design high-density chips:
the direct approach and the indirect approach [4–7]. The direct
gene-centric approach, which focuses on genetic variants in genic
regions [4,5] , can capture putative variants directly. The indirect
approach using quasi-random SNPs or LD-based tagSNPs aims to
capture most of the common variants in both genic and nongenic
regions [6,7]. It provides higher coverage of genome and explores
genic variants as well as potential variants in regions outside
known genes.
It is clear that both approaches can cover the genome densely
either directly or through linkage disequilibrium (LD) [8,9] and be
successful in identifying disease variants in genes [1–3]. It is not
clear, however, the extent to which these approaches can capture
the common genic variants. Moreover, it is also important to
characterize and compare differences among the approaches used
in GWA studies. Nicolae et al. [10] investigated Affymetrix
GeneChip Human Mapping 100K and found that SNPs in the set
were undersampled from coding regions and oversampled from
regions outside genes. Jorgenson and Witte [11] evaluated the
coverage of both genic and nongenic SNPs, and estimated that
random and tagSNP strategy for the indirect approaches could
provide lower coverage of genic SNPs than nongenic SNPs. In this
study, we perform a gene-centric evaluation to characterize the
above approaches used in GWA studies.
Our evaluation is performed on three whole-genome commer-
cial chips representing the above SNP-selection approaches:
Illumina Human-1 Genotyping BeadChip (Human-1, gene-
centric SNP panel) [12], Affymetrix GeneChip Human Mapping
500K Array Set (GeneChip 500K, quasi-random SNP panel) [13]
and Illumina Human Hap550 (Hap550, LD-based tagSNP panel)
[12]. By using both the empirical Phase II HapMap CEU data
(Utah residents with ancestry from northern and western Europe)
[14] and the disease variants extracted from OMIM [15], we
evaluated the coverage of the approaches in genic regions and the
ability to capture disease variants in Caucasian population. Since
SNPs in diseases associated pathways and functionally important
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are more attractive, we further compared the distribution patterns
of SNPs with these characteristics. Our study reveals the common
and different characteristics between the approaches used in GWA
studies.
RESULTS
Evaluating coverage and capturing disease variants
in genic regions
Figure 1 shows coverage of three high-throughput SNP chips in
genic regions (MAF$0.05, CEU). Although three chips cover about
6,25% of Phase II HapMap SNPs directly (chip), the coverage
increases quickly to 37,96% when counting tagged SNPs (r
2$0.8
and r
2$0.5). Since Hap550 uses the tagSNPs selected from Phase
I+II HapMap data set , it gets the coverage of near 91% (r
2$0.8) as
expected. If r
2 threshold set to 0.5, Human-1 and GeneChip 500K
also gets the coverage of 53% and 84%, respectively. On average,
Hap550 and GeneChip can get additional 3,4 folds nonredundant
LD SNPs; while Human-1 can get 5,8f o l d s .
There are totally 1338 nonredundant SNPs in OMIM that are
defined as disease variants and associated with either diseases or
phenotypes. Among these 1338 nonredundant SNPs, 159 of which
can be mapped to the Phase II HapMap CEU data. We then
evaluate the ability of SNP chips to capture 100 of 159 disease
variants with MAF$0.5. Human-1 and Hap550 can directly
capture 48% and 62% of variants, respectively (Figure 2A),
whereas GeneChip can only capture 11%. Via LD-tagging, all
chips can capture more than 55% (r
2$0.8) and 75% (r
2$0.5) of
SNPs. According to additional 59 disease variants with
MAF,0.05, 75% of them are uncaptured (Table S1).
Figure 2B shows the overlap of captured variants (r
2$0.5).
There are 65 of SNPs captured by all SNP chips, whereas 6 of
them are not captured by any chips. It shows that the indirect
approaches have the same ability as the direct approach to capture
most of common disease variants in genes in HapMap.
Distribution patterns of SNPs in genic regions
SNPs are first classified into genic or nongenic regions with the
annotation of dbSNP. In the analyses, less than 45% of SNPs in
GeneChip 500K and Hap550 locate in genic regions, while 72%
of Human-1 lie in genic regions (Figure S1). When counting
tagged SNPs, the difference is reduced to near ten percent. SNPs
in genic regions can further be classified into one of the five
functional classifications: flank, utr, synonymous, nonsynonymous
and intron. The distribution patterns of GeneChip 500K and
Hap550 are very similar (Figure 3): similar high proportion of
intron classification and similar distribution in other classifications.
Almost 90% SNPs of GeneChip 500K and Hap550 locate in
intron, meanwhile 7% SNPs lie in flank region, which makes it
second-rich region. Each classification of utr, synonymous and
nonsynonymous carries 1,2 percent SNPs. As expected, Human-
1 carries relative small proportion of SNPs in intron region (70%)
and high proportions in other regions (5,10%). It highlights the
pertinent gene-centric design of the functional chip. Owing to the
increasing proportion of intron region in Human-1, all three chips
have the same distribution pattern when including tagged SNPs
(r
2$0.8).
Distribution patterns of SNPs in GO categories and
KEGG pathways
To examine whether SNPs of Human-1, GeneChip 500K and
Hap550 distribute in the same ontologies and pathways via genes,
we mapped SNPs to gene ontology (GO) annotation [16] and
Kyoto Encyclopedia of Genes and Genomes (KEGG) [17]
pathways. The distribution of SNPs in all GO component,
function and process categories (Figure 4A) and KEGG pathways
(Figure 4B) remained largely the same between GeneChip 500K
(middle rings) and Hap550 (outer rings), and slightly different with
Human-1 (inner rings). We tested the hypothesis that equal
percentages of SNPs on the chips distribute in KEGG human
diseases pathways (Table 1). GeneChip 500K and Hap550 show
no significant differences in all pathways except for pathogenic
Escherichia coli infection pathway. However, significant differ-
ences are found between the direct and the indirect approaches.
Human-1 exhibits enrichment in several pathways such as
Huntington’s disease and pancreatic cancer pathways, whereas
GeneChip 500K and Hap550 enrich in Parkinson’s disease,
Dentatorubropallidoluysian atrophy (DRPLA) and non-small cell
lung cancer pathways. Furthermore, the difference enlarges
(Table S2) if LD-tagged SNPs are taken into consideration.
More pathways exhibit significant difference between the direct
and the indirect approaches.
Distribution patterns of SNPs in evolutionary
conserved introns and nongenic regions
Highly evolutionarily conserved regions across species may
contain unknown genes, for example, microRNA coding genes,
or regulatory elements such as cis enhancers. It is important to
survey the SNPs in conserved regions both outside genes and in
introns. We plot SNP percentage against conservation score of
Figure 1. Coverage of three high-throughput SNP chips in genic regions. Three chips cover Phase II HapMap SNPs either directly (chip) or through
linkage disequilibrium (r
2$0.8 and r
2$0.5).
doi:10.1371/journal.pone.0001262.g001
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about two percent SNPs of GeneChip 500K and Hap550 locate in
conserved intron and nongenic bases. Due to enrichment of SNPs
in conserved sequence, Human-1 contains more fractions of SNPs
lying in the evolutionarily conserved bases (17.5% for nongenic
regions, 6.9% for intron). When considering tagged SNPs, the
difference between chips is inconspicuous (Figure S2) and about
3% of SNPs have scores exceed conserved threshold.
DISCUSSION
Various GWA studies have been performed to examine the role of
common genetic variants in complex diseases and traits, taking
advantage of recent advances in high-throughput SNP genotyping
technologies. It has been proved that both the direct and the
indirect approaches are capable of identifying disease variants in
genes. For example, an intron SNP (rs7903146) and nearby SNPs
in LD with it in transcription factor 7-like 2 gene (TCF7L2) gene
had been replicated in several researches with different approaches
[1–3]. In our study, we show that the current high-density SNP
chips provide very high coverage in genic regions and can capture
most of known common disease variants under HapMap frame,
no matter which SNP selection strategy is used. Acting as a hybrid
of the indirect and the direct approaches to evaluate whole-
genome association, Human-1 highlights SNPs enriched in genes
and evolutionarily conserved regions. Therefore, we consider it as
a typical chip of direct gene-centric approach and calculate tagged
SNPs in HapMap. Although the indirect approaches using quasi-
random SNPs or LD-based tagSNPs focus on common variants,
irrespective of their genic location, they perform as good as the
direct approach in genic regions via their high density and
coverage. Our evaluation of coverage and characteristics is based
on the Phase II HapMap data, which is the largest catalogue of
common SNPs with genotyping information till now. Since most
of SNPs on three chips show concordance with HapMap SNPs, it
is reasonable though not very fair to use HapMap for
characterizing the chips. To simplify the procedure, we only used
the pairwise aggressive algorithm and two LD thresholds (r
2$0.8
and r
2$0.5) to capture tagged SNPs in CEU. On the whole, all
Figure 2. Disease variants in HapMap captured by three high-throughput chips. A. Shows the percentage of disease variants captured by three
chips either directly (chip) or through linkage disequilibrium (r
2$0.8 and r
2$0.5). B. Displays the overlapped results captured by three chips (r
2$0.5).
doi:10.1371/journal.pone.0001262.g002
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HapMap in genic regions.
It is hard to estimate the ability of the approaches to capture
disease variants. Then it is available to estimate whether the
known susceptibility SNPs to common diseases are covered by
ongoing GWA studies using chips. There are some public
databases such as OMIM [15], GAD [18], HGV [19], HGMD
[20] collecting variants that lead to human diseases and
phenotypes variation. However, the number of susceptibility SNPs
is limited in nowadays databases. Thus, we calculate and compare
the ability of the chips to capture 1338 nonredundant SNPs in
OMIM that affect susceptibility of human diseases, most of which
are nonsynonymous mutations. With respect to common SNPs
(MAF$0.05) HapMap genotyped, the chips perform well and can
capture most of them. According to rare SNPs, they are mostly
ignored by the chips in current stage. It had been suggested that
a genome-wide genotyping product could be coupled with a gene-
centric SNP set such as SeattleSNPs Program for Genomic
Application [21] to improve the ability of covering rare SNPs.
Several factors besides genomic coverage and map density can
affect the power of gene-centric GWA studies. One is the
proportion of SNPs in functionally important genic regions and
conserved noncoding sequences. Nonsynonymous coding SNPs
and SNPs in promoters are most traditionally attractive for their
potential altering protein function [22], altering transcript splicing
[23] destabilizing protein 3D structure and reduce protein
solubility [24], and altering regulatory ability [25]. Evolutionarily
conserved regions across species may contain functionally
important elements, for example, cis- regulatory elements [26]
and replication start points [27], or unknown genes such as
microRNA coding genes [28]. Many computational approaches
based on multi-species alignment have been developed to search
regulatory elements in evolutionarily conserved regions [29,30].
Follow-up experiments also validated the potential function of
transcriptional regulation and development association [31,32]. It
is also important to characterize the conservation property of
SNPs outside genes and in introns [33]. Our results show that the
indirect approaches have highly similar patterns in these important
function sequences. Although difference exhibits between the
indirect and the direct approaches for SNPs on the chip, it
becomes inconspicuous after considering tagged SNPs.
Another important factor is the enrichment of SNPs in
ontologies and pathways. Ontologies and pathways are essential
and widely used for differential expression in pathway level [34],
protein-protein interaction (PPI) analysis [35] and constructing
PPI network [36]. Thus, it is reliable to analyze gene-gene
interaction [37] and construct genetic interaction network via
SNPs-enriched ontologies and pathways [38,39]. Lesnick et al.
proposed a genomic pathway approach to construct models of
axon-guidance pathway SNPs that can predict the susceptibility of
Parkinson disease [39]. It hints the potential ability of mining
disease associated ontologies and pathways using high-density SNP
Figure 3. Distribution patterns of SNPs in genic regions. SNPs in genic regions are annotated with five functional classifications: flank (within 2 kb 59
or 500 bp 39 of a gene, originally named locus in dbSNP), utr (59 and 39 untranslated region), synonymous (synonymous coding SNP),
nonsynonymous (nonsynonymous coding SNP) and intron (including splice-site SNPs).
doi:10.1371/journal.pone.0001262.g003
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and Hap550 distribute in the same ontologies and pathways via
genes and tested the hypothesis that the same fraction of SNPs on
the chips distribute in the KEGG human disorder pathways. On
most occasions, Human-1 has the similar fractions as GeneChip
500K and Hap550. Significant differences are observed in some
pathways especially when considering tagged SNPs. Since Hap550
almost cover HapMap and Human-1 contains a limited subset
(Figure 1), it implies that SNPs of Human-1 are not evenly
distributing in genes and pathways.
In this year, Affymetrix (http://www.affymetrix.com) and
Illumina (http://www.illumina.com) released their one million
commercial SNP chips, which are most high density SNP chips
available till now. We can expect that the SNP chips will cover
most of the human common SNPs and density will not be
a common topic in the coming future (maybe in five years). One
possible future direction of developing SNP chips is population-
specific chips. The current chips aim at common SNPs of three
representative populations (CEU, JPT+CHB, YRI), while CEU
matches the SNP sets best and YRI worst. Although YRI-specific
SNP chip has been designed, the population-specific (especially the
populations other than three major populations) chips are needed
since various researches have shown that the portability of
tagSNPs across some populations is not satisfying [40–43].
Another possible direction is developing rare SNPs-based chips,
however, potential large sample size still obstructs this way. A most
realistic direction is developing disease/pathway specific chips for
specific researches. This is quite different with previous candidate
Figure 4. Distribution patterns of SNPs in ontologies and pathways. Outer rings: SNPs on Hap550. Middle rings: SNPs on GeneChip 500K. Inner
rings: SNPs on Human-1. Each section represents the number of SNPs on the chips assigned to a given GO category or KEGG pathways. A.
Distribution patterns in GO cellular component, molecular function and biological process categories. B. Distribution patterns in KEGG pathways.
doi:10.1371/journal.pone.0001262.g004
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will have the advantages of both high density and research
specificity. That means all possible disease-oriented SNPs in
pathways/genes are included, which is based on the knowledge
and Bioinformatics annotations of the diseases. This will separate
the ‘‘discovering susceptible SNPs’’ stage by WGA chips and
‘‘replicating associations and constructing genetic models’’ stage
by specific chips similarly as we did with resequencing and
genotyping. This will reduce the cost and increase the sample size
greatly. Thus, WGA studies era will be realistic. For the above
reason, Bioinformatics will be deeply involved in the designing of
the chips, analyzing the data and constructing the models. Our
analysis in this research will be an exploration in this future field.
MATERIALS AND METHODS
Data sets
Three genome-wide SNP chips (Human-1, GeneChip 500K and
Hap550) were selected for evaluations, representing gene-centric,
quasi-random SNPs and LD-based tagSNPs approaches, re-
spectively. SNP lists were downloaded from their websites. Since
most of SNPs on three chips show concordance with HapMap
SNPs, we used Phase II HapMap CEU (release 21) data [14] to
evaluate coverage of SNP chips in Caucasian population.
LD-tagged SNPs and coverage calculation
All SNPs of three chips were mapped to HapMap to ensure SNPs
on the chip, and these SNPs were considered as tag SNPs to
capture LD-tagged SNPs. Frequency and LD data of SNPs were
downloaded from HapMap website. We simply used pairwise
aggressive algorithm [44] to ascertain SNPs that have pairwise r
2
larger than the specific thresholds (r
2$0.8 and r
2$0.5). Since
Human-1 acts as a hybrid of the indirect and the direct
approaches, we also calculate its tagged SNPs to get the maximum
coverage. When calculating coverage, only common SNPs
(MAF$0.05) were considered. Coverage is estimated by SNPs
(chip+tagged) divided by all SNPs in HapMap.
Bioinformatics annotation for SNPs
All SNPs were annotated using National Center for Biotechnology
Information (NCBI) dbSNP (build 126) [45]. Each SNP from
various data sets was mapped to dbSNP via ref SNP (rs). SNPs
without an rs number or not presented in current dbSNP would be
Table 1. Distribution differences of SNPs (chip) in KEGG human diseases pathways.
..................................................................................................................................................
Disease Number of SNPs in pathways Pairwise comparison p-value
1
Human-1 500K Hap550
Human-1:
500K
Human-1:
Hap550
500K:
Hap550
Alzheimer’s disease 102 241 269 0.0412 1.7E-05 0.0039
Amyotrophic lateral sclerosis (ALS) 60 187 229 0.8215 0.3705 0.0972
Basal cell carcinoma 131 320 445 0.0456 0.014 0.6157
Cholera 122 332 494 0.3419 0.4852 0.6721
Chronic myeloid leukemia 247 595 869 0.0039 0.0041 0.8283
Colorectal cancer 306 852 1251 0.2512 0.3478 0.7086
Dentatorubropallidoluysian atrophy (DRPLA) 117 584 828 7.1E-07 9.4E-07 0.7463
Endometrial cancer 239 880 1353 0.0075 2.5E-04 0.1582
Epithelial cell signaling in Helicobacter pylori infection 214 511 716 0.0051 9.7E-04 0.6152
Glioma 248 698 1077 0.3688 0.9832 0.1811
Huntington’s disease 112 197 227 5.3E-06 2.1E-11 0.0213
Maturity onset diabetes of the young 46 93 165 0.0266 0.2494 0.1122
Melanoma 239 740 1024 0.7226 0.8386 0.3951
Neurodegenerative Disorders 162 637 886 0.0029 0.0084 0.4862
Non-small cell lung cancer 218 986 1508 1.1E-07 3.2E-10 0.1731
Pancreatic cancer 255 579 766 2.3E-04 5.4E-07 0.1213
Parkinson’s disease 69 354 516 5.0E-05 2.2E-05 0.8882
Pathogenic Escherichia coli infection 91 357 367 0.0259 0.5231 5.8E-06
Prion disease 55 125 201 0.0821 0.255 0.3452
Prostate cancer 273 739 1147 0.1415 0.6181 0.1344
Renal cell carcinoma 223 573 782 0.0485 0.0055 0.3185
Small cell lung cancer 425 1306 1901 0.738 0.6184 0.823
Thyroid Cancer 85 262 362 0.8575 0.8627 0.5938
Type I diabetes mellitus 117 316 498 0.3177 0.8356 0.2273
Type II diabetes mellitus 186 620 1004 0.2372 0.008 0.0278
Total 4342 13084 18885
1.Chi-square tests between pairwise chips were performed to test whether two chips have same percentages of SNPs in the pathways. Bonferroni correctionw a s
proceeded to correct multiple testing. P-values smaller than significant level (P,0.002) are in bold type.
doi:10.1371/journal.pone.0001262.t001
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PLoS ONE | www.plosone.org 6 December 2007 | Issue 12 | e1262ignored. A SNP was first annotated in gene or nongenic regions.
Then genic SNP would further be annotated with five functional
classifications: flank (within 2 kb 59 or 500 bp 39 of a gene,
originally named locus in dbSNP), utr (59 and 39 untranslated
region), synonymous (synonymous coding SNP), nonsynonymous
(nonsynonymous coding SNP) and intron (including splice-site
SNPs).
OMIM (Nov, 2006) [15] deposited 1338 nonredundant SNPs
that affect human diseases or phenotypes variation, most of which
are nonsynonymous mutations. These SNPs were mapped to
HapMap data and evaluated the capturing ability of the SNP
chips. The procedure was same as coverage calculation.
We examined whether SNPs of Human-1, GeneChip 500K and
Hap550 distribute in the same ontologies and pathways via genes.
SNPs were mapped to GO annotations and KEGG pathways via
NCBI dbSNP [45] and Entrez Gene [46]. We plotted the
distribution of SNPs in categories with three concentric rings for
the chips. In addition, we compared distribution difference
between the paired chips in KEGG human disorders pathways.
Chi-square tests between pairwise chips were performed to test
whether two chips have same percentages of SNPs in the
pathways. Bonferroni correction was proceeded to correct multiple
testing.
Base-by-base conservation scores for human bases were down-
loaded from UCSC Conservation Track [47] which used
phastCons [48] to calculate conservation scores across 28
mammalian species. SNPs in nongenic and intron regions were
mapped to the bases to attain conservation scores. Conservation
scores can be considered as probabilities that each SNP lies in
a conserved element [48].
SUPPORTING INFORMATION
Figure S1 Percentage of SNPs in genic and nongenic regions.
Shows the percentage of disease variants captured by three chips
either directly (chip) or through linkage disequilibrium (r
2$0.8).
Found at: doi:10.1371/journal.pone.0001262.s001 (1.18 MB
DOC)
Figure S2 Distribution patterns of SNPs in evolutionary
conserved introns and nongenic regions. The percentage of SNPs
(r
2$0.8) on three chips is plotted against conservation score.
Found at: doi:10.1371/journal.pone.0001262.s002 (1.31 MB
DOC)
Table S1 MAF of 159 disease SNPs (r
2$0.5) in HapMap
Found at: doi:10.1371/journal.pone.0001262.s003 (0.03 MB
DOC)
Table S2 Distribution differences of SNPs (r
2$0.8) in KEGG
human diseases pathways. 1. Chi-square tests between pairwise
chips were performed to test whether two chips have same
percentages of SNPs in the pathways. Bonferroni correction was
proceeded to correct multiple testing. P-values smaller than
significant level (P,0.002) are in bold type.
Found at: doi:10.1371/journal.pone.0001262.s004 (0.07 MB
DOC)
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